Lmr Partners LLP Dia Medica Therapeutics Inc. Transaction History
Lmr Partners LLP
- $8.3 Billion
- Q1 2025
A detailed history of Lmr Partners LLP transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Lmr Partners LLP holds 15,167 shares of DMAC stock, worth $63,398. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,167Holding current value
$63,398% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DMAC
# of Institutions
62Shares Held
6.06MCall Options Held
14.9KPut Options Held
1K-
Vanguard Group Inc Valley Forge, PA1.35MShares$5.65 Million0.0% of portfolio
-
First Manhattan CO New York, NY606KShares$2.53 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX600KShares$2.51 Million5.72% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA557KShares$2.33 Million0.0% of portfolio
-
Bleichroeder LP New York, NY382KShares$1.6 Million0.5% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $111M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...